Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Prediction of Early Mortality with Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1336 Patients from MRC/NCRI and SWOG

Xu Wang, Ian Thomas, Cono Ariti, Mike Dennis, Priyanka Mehta, Nigel H Russel, Mia Sydenham, Robert Hills, Alan K. Burnett, Sucha Nand, Sarit Assouline, Laura C. Michaelis, Harry P. Erba, Kathleen Kerr, Roland B. Walter, Megan Othus

Blood (2021) 138 (Supplement 1): 220.

https://doi.org/10.1182/blood-2021-151597

Published: 2021

Journal Articles

Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area

Blood (2020) 136 (Supplement 1): 58–59.

https://doi.org/10.1182/blood-2020-135929

Published: 2020

Journal Articles

Germline Mutations Predispose to Familial Myeloproliferative Neoplasms

Stephanie Berg, DO, Manuel O. Diaz, MD, Sucha Nand, MD, Jiwang Zhang, MD

Blood (2019) 134 (Supplement_1): 2969.

https://doi.org/10.1182/blood-2019-124805

Published: 2019

Journal Articles

Treatment Free Remission for Chronic Phase Chronic Myelogenous Leukemia Patients Who Stopped Tyrosine Kinase Inhibitor Therapy Due to Intolerance

Daulath Singh, MD, Sucha Nand, MD, Hanh Mai, DO

Blood (2019) 134 (Supplement_1): 5919.

https://doi.org/10.1182/blood-2019-129533

Published: 2019

Journal Articles

Safety of Gemtuzumab Ozogamicin As Monotherapy or Combination Therapy in an Expanded-Access Protocol for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Eunice S. Wang, MD, Richard Aplenc, MD PhD, Deborah Chirnomas, Michael John Dugan, MD, Salman Fazal, MD, Swaminathan Iyer, Tara L Lin, MD, Sucha Nand, MD, Kristen J Pierce, Paul J Shami, MD, Jennifer J Vermette, Camille N Abboud, MD

Blood (2018) 132 (Supplement 1): 3979.

https://doi.org/10.1182/blood-2018-99-110804

Published: 2018

Journal Articles

Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies

Abby Statler, Megan Othus, Harry P. Erba, Thomas R. Chauncey, Jerald P. Radich, Steven Coutre, Anjali Advani, Sucha Nand, Farhad Ravandi, Sudipto Mukherjee, Mikkael A. Sekeres

Blood (2018) 131 (25): 2782–2788.

https://doi.org/10.1182/blood-2018-01-826693

Published: 2018

Includes: Supplemental data

Journal Articles

Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies

Abby Statler, MPH, MA, Megan Othus, PhD, Harry P. Erba, MD PhD, Thomas R. Chauncey, MD PhD, Jerald P. Radich, MD, Steven E. Coutre, MD, Anjali S. Advani, MD, Sucha Nand, MD, Farhad Ravandi, MD, Sudipto Mukherjee, MD, PhD, M.P.H., Mikkael A. Sekeres, MD MS

Blood (2016) 128 (22): 4002.

https://doi.org/10.1182/blood.V128.22.4002.4002

Published: 2016

Journal Articles

Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival

Megan Othus, PhD, Mikkael A Sekeres, MD MS, Sucha Nand, MD, Guillermo Garcia-Manero, MD, Frederick R. Appelbaum, MD, Harry P. Erba, MD PhD, Elihu H. Estey, MD

Blood (2016) 128 (22): 1613.

https://doi.org/10.1182/blood.V128.22.1613.1613

Published: 2016

Journal Articles

Increased Risk of Sternal Complications in Patients with Plasma Cell Dyscrasias (PCDs) Undergoing Coronary Artery Bypass Graft (CABG)

Malini M Patel, MD, Shams B Bufalino, MD, Anai N Kothari, MD, Paul C Kuo, MD, Sucha Nand, MD

Blood (2015) 126 (23): 5319.

https://doi.org/10.1182/blood.V126.23.5319.5319

Published: 2015

Journal Articles

Prevalence of Multiple Primary Hematologic Malignancies Seen at a Tertiary Care Center

Kathrine A Cooper, MD, Jonathan Lattell, BS, Beverly Gonzalez, ScM, Stephanie Kliethermes, PhD, Sucha Nand, MD

Blood (2015) 126 (23): 5017.

https://doi.org/10.1182/blood.V126.23.5017.5017

Published: 2015

Journal Articles

Sensitizing Acute Myeloid Leukemia Cells to Interferon-Induced Differentiation By Inhibiting RIP1/RIP3 Necroptotic Pathway

Blood (2014) 124 (21): 3752.

https://doi.org/10.1182/blood.V124.21.3752.3752

Published: 2014

Journal Articles

Germ-Line and Somatic Mutations in Familial Myeloproliferative Neoplasms (MPNs). a Pilot Study

Sucha Nand, MD, Manuel O. Diaz, MD, David E. Marinier, MD, Mark A. Walshauser, MD, Amy B Rosenfeld, Laura C Michaelis, MD, Patrick J Stiff, MD, Xiaowu Gai, MD

Blood (2014) 124 (21): 3214.

https://doi.org/10.1182/blood.V124.21.3214.3214

Published: 2014

Journal Articles

Heckathorn disease revisited

Sucha Nand, Kevin Barton, Richard Schultz, Mary Klein, Ameet Kini

Blood (2014) 123 (9): 1429–1431.

https://doi.org/10.1182/blood-2013-12-545095

Published: 2014

Journal Articles

AML Cells Utilize TNF-Driven JNK Signaling As a Critical NF-κB-Independent Survival Signal

Andrew Volk, Jing Li, PhD, Junping Xin, PhD, Dewen You, PhD, Jun Zhang, PhD, Peter Breslin, PhD, Zejuan Li, MD, PhD, Wei Wei, Rachel Schmidt, Xinyu Li, MD, Zhou Zhang, PhD, Paul C Kuo, MD, Sucha Nand, MD, Jianke Zhang, PhD, Jianjun Chen, PhD, Jiwang Zhang, MD, PhD

Blood (2013) 122 (21): 2890.

https://doi.org/10.1182/blood.V122.21.2890.2890

Published: 2013

Journal Articles

A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia

Sucha Nand, Megan Othus, John E. Godwin, Cheryl L. Willman, Thomas H. Norwood, Dianna S. Howard, Steven E. Coutre, Harry P. Erba, Frederick R. Appelbaum

Blood (2013) 122 (20): 3432–3439.

https://doi.org/10.1182/blood-2013-06-506592

Published: 2013

Journal Articles

Sensitizing Leukemic Cells to NF-κB Inhibitor Treatment by Repressing TNFα-Mediated, NF-κB-Independent Survival Signaling

Andrew Volk, Yechen Xiao, PhD, Junping Xin, PhD, Dewen You, PhD, Rachel Schmidt, Shubin Zhang, Wei Wei, Peter Breslin, PhD, Sucha Nand, MD, Jiwang Zhang, MD, PhD

Blood (2012) 120 (21): 1878.

https://doi.org/10.1182/blood.V120.21.1878.1878

Published: 2012

Journal Articles

A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients

Sucha Nand, MD, Megan Othus, PhD, John E. Godwin, MD, MS, Cheryl L Willman, MD, Thomas Norwood, Harry Paul Erba, MD, PhD, Dianna Howard, MD, Steven E. Coutre, MD, Frederick R. Appelbaum, MD

Blood (2012) 120 (21): 3584.

https://doi.org/10.1182/blood.V120.21.3584.3584

Published: 2012

Journal Articles

Title: Promoter Methylation of Selected Genes and Response to Azacitidine (AZ) Therapy in Patients with Non-BCR-ABL Myeloproliferative Disorders (MPDs)

Nicholas Achille, BS, Laura Michaelis, MD, Scott E. Smith, MD, PhD, FACP, Eliza Germano, Nancy J. Zeleznik-Le, PhD, Sucha Nand, MD

Blood (2011) 118 (21): 4625.

https://doi.org/10.1182/blood.V118.21.4625.4625

Published: 2011

Journal Articles

Limitations of Performance Status (PS) Assignment in Predicting Outcomes of Acute Myeloid Leukemia (AML) and the Role of Objective Parameters in Predicting PS Assignment,

Kathleen Wren Phelan, MD, Sucha Nand, MD, Laura C Michaelis, MD

Blood (2011) 118 (21): 4191.

https://doi.org/10.1182/blood.V118.21.4191.4191

Published: 2011

Journal Articles

Azacitadine and Low-Dose Gemtuzumab Ozogamicin for the Treatment of Poor-Risk Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Relapsed, Refractory Disease.

Laura C Michaelis, MD, Danielle Shafer, DO, Kevin Barton, MD, Tulio Rodriguez, MD, Scott Smith, M.D., Ph.D, Patrick Stiff, MD, Sucha Nand, MD

Blood (2009) 114 (22): 1034.

https://doi.org/10.1182/blood.V114.22.1034.1034

Published: 2009

NARROW

Prediction of Early Mortality with Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1336 Patients from MRC/NCRI and SWOG

Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area

Germline Mutations Predispose to Familial Myeloproliferative Neoplasms

Treatment Free Remission for Chronic Phase Chronic Myelogenous Leukemia Patients Who Stopped Tyrosine Kinase Inhibitor Therapy Due to Intolerance

Safety of Gemtuzumab Ozogamicin As Monotherapy or Combination Therapy in an Expanded-Access Protocol for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies

Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies

Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival

Increased Risk of Sternal Complications in Patients with Plasma Cell Dyscrasias (PCDs) Undergoing Coronary Artery Bypass Graft (CABG)

Prevalence of Multiple Primary Hematologic Malignancies Seen at a Tertiary Care Center

Sensitizing Acute Myeloid Leukemia Cells to Interferon-Induced Differentiation By Inhibiting RIP1/RIP3 Necroptotic Pathway

Germ-Line and Somatic Mutations in Familial Myeloproliferative Neoplasms (MPNs). a Pilot Study

Heckathorn disease revisited

AML Cells Utilize TNF-Driven JNK Signaling As a Critical NF-κB-Independent Survival Signal

A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia

Sensitizing Leukemic Cells to NF-κB Inhibitor Treatment by Repressing TNFα-Mediated, NF-κB-Independent Survival Signaling

A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients

Title: Promoter Methylation of Selected Genes and Response to Azacitidine (AZ) Therapy in Patients with Non-BCR-ABL Myeloproliferative Disorders (MPDs)

Limitations of Performance Status (PS) Assignment in Predicting Outcomes of Acute Myeloid Leukemia (AML) and the Role of Objective Parameters in Predicting PS Assignment,

Azacitadine and Low-Dose Gemtuzumab Ozogamicin for the Treatment of Poor-Risk Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Relapsed, Refractory Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only